Navigation Links
Chemokine Therapeutics Announces Preliminary Results of CTCE-9908,Phase Ib/II Clinical Trial in Late Stage Cancer Patients

TSX: CTI OTCBB: CHKT

VANCOUVER, March 12, 2007 /PRNewswire-FirstCall/ - Chemokine Therapeutics Corp. ("Chemokine Therapeutics" or the "Company") , a biotechnology company developing chemokine-based therapies to treat cancer, blood disorders, and vascular disease today announced positive preliminary data and the successful completion of the dose-escalation portion of its Phase Ib/II clinical trial for CTCE-9908, the Company's anti-cancer drug candidate. No dose limiting toxicities were observed in any of the cancer patients and two out of three patients with ovarian cancer responded positively and exhibited stable disease.

Chemokine Therapeutics will now proceed with the remaining portion of the clinical trial in which up to twenty additional patients will be treated at 5mg/kg/day. The Company expects to enroll the remainder of the patients and complete the current trial by the end of Q3 2007. The Company has also accelerated its efforts to initiate a large Phase II program in the U.S. by the end of 2007. Accordingly, a pre-IND meeting has been scheduled with the FDA to discuss the Company's future clinical trial program.

"We are very pleased that no dose-limiting toxicities were observed in the first part of the trial and encouraged by the positive outcome in the small group of ovarian cancer patients," said Dr. Hassan Salari, Chemokine Therapeutics President and CEO. "It is quite remarkable to see clinical evidence of efficacy considering these patients have exhausted every therapeutic avenue. We are now looking to rapidly expand the number of patients in Phase II clinical trials of CTCE-9908 to examine the potential broader applicability of this novel oncology drug in the treatment of cancer patients."

The primary purpose of this study is dose-selection and evaluation of safety and tolerability of CTCE-9908. CTCE-9908 is administered via a 30-minute infusion on weekdays over a treatment p
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:11/25/2008)... Proteolix, Inc., a,leader in the...hat target,protein degradation pathways in cancer...ta from two ongoing Phase 2 clinical trials of car... the upcoming 50th Annual Meeting of the,American...first in a new class,of specific proteasome inhib...
(Date:11/25/2008)...ial to Assess Survival of Patients Receiving Litx ... Hepatocellular Carcinoma , , BELLEVUE, Was...y, Inc. (LSO) today announced the completion of en...ht Infusion Therapy(TM) (Litx(TM)) as a treatment ...lso known as hepatoma or primary liver cancer. , ...
(Date:11/24/2008)...e/ -- Domino,s Pizza (NYSE: DPZ ), the,recogniz...o raise dough for,the kids of St. Jude Children,s... and Giving campaign. Domino,s customers will have...urchase to benefit the children of St. Jude.,Dona...when ordering online at, www.dominos.com . The ca...
(Date:11/24/2008)...dership and long-term commitment to hepatitis rese...ire-FirstCall/ -- Schering-Plough Corporation (NYS...eprevir, its lead investigational oral hepatitis C...ment. The company believes boceprevir has the pot...otease inhibitor for treating chronic hepatitis C....
Breaking Medicine Technology:Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 2Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 3Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma 4Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 2Domino's Pizza Pledges Support to the Fifth Annual St. Jude Children's Research Hospital(R) Thanks and Giving(R) Campaign 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 2Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 3Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 4Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 5Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 6Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 7Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 8Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C 9United BioSource Acquires Caro Research Leader in Simulation Modeling 620 1United BioSource Acquires Caro Research Leader in Simulation Modeling 620 2CEL SCI CEO to Present Tomorrow at the Biotech Pharma Healthcare On Line Forum 283 1CEL SCI CEO to Present Tomorrow at the Biotech Pharma Healthcare On Line Forum 283 2The Nutrition Conscious Take a Bite Out of Fast Food 1394 1The Nutrition Conscious Take a Bite Out of Fast Food 1394 2The Nutrition Conscious Take a Bite Out of Fast Food 1394 3The Nutrition Conscious Take a Bite Out of Fast Food 1394 4Metropolitan Hosts Informational Meetings in Nassau County 1391 1
... Fail to Demonstrate Meaningful Placebo Adjusted W...W YORK, July 09, 2007 /PRNewswire-FirstCall/ -- Ma...lts of the company,s two,Phase 2a clinical trials ...andomized, double-blind, placebo-controlled studie...besity, demonstrated no,statistically or clinicall...
...ction of rHuPH20 with Humira Estimated to Increase...lity from 64% to 100%,-, SAN DIEGO, July 09, 2007 ...nc. , a biopharmaceutical company developing and,c...nounced that,final results of the Enhanze(TM) Tech...ption and bioavailability of a,representative comm...
Other Medicine Technology:Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 2Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 3Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for,Oral Oleoyl-estrone 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
(Date:12/2/2008)... 2 The Healthcare group at,Frost ... is pleased to announce that,it will be hosting a...,sub-Saharan Africa on Friday 12 December at 16h0...om.com/cgi-bin/prnh/20081117/FSLOGO ) , Med...services is a,relatively novel concept in most su...
(Date:12/2/2008)...athon Health, a leading provider of onsite health ...hat New Balance, the athletic products company, ha...nd manage onsite health clinics and to provide hea...in Maine , Burlington, VT...ading provider of onsite employee health services ...
(Date:12/2/2008)... many families, the problem with the holidays is f...ight into how caregivers of aging parents can brin...experience. , San Mateo, ...he stress of the holiday season is family, especia...xpert Esther Koch , founder of Encore Management...
(Date:12/2/2008)...ional Non-profit Launches Age-related Macular Dege...ost to Eligible Patients and Free Eye-Healthy Cook... (Vocus) December 2, 2008 -- "Do You See What...isease known as Age-related Macular Degeneration (... ,Picture this…. a large black hole in the ...
Breaking Medicine News(10 mins):Health News:The Future of Financing Health Services in Africa 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 2Health News:Marathon Health Joins Forces with New Balance for Employee Health - Associate Health Services Provided at Three Maine Locations 3Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 2Health News:Holidays with Aging Parents: Elder Care Expert Has the Prescription for Caregiver Stress 3Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 2Health News:This Holiday Season EyeCare America Asks Seniors, 'Do you see what I see?' 3
...ewed journal of American Cancer Society) reveals t...t clinically significant screening// criteria for ...uding major depression and post-traumatic stress d...ally all of the women admitted have been experienc...
...hat has FDA approval for treating rheumatoid arthr...ith juvenile rheumatoid// arthritis, according to ...ge of Rheumatology Annual Scientific Meeting in Wa...adalimumab, currently used to treat adults with mo...
...detect synacthen, which when injected simulates th...steroid. This is// most common in sports where spo...-enhancing tool. Synacthen and injecting performan... other than medical treatment is banned. Though ...
...und that pregnant women with systemic lupus are at...ions compared to normal// pregnant women. The stu...ted nationwide covering more than 18 million women...n with systemic lupus should be considered a high-...
Other Medicine News:Health News:Breast Cancer Patients Suffer From Psychological Problems 2Health News:Adalimumab Proves Effective for Children with Juvenile Rheumatoid Arthritis 2Health News:Sports Cheats Beware - New Test To Detect Synacthen Found 2Health News:Pregnant Women With Lupus Are At Greater Risk 2Health News:Pregnant Women With Lupus Are At Greater Risk 3
Product includes all 15 Lexi-Comps databases. Includes Lexi-drugs, the official reference of the American Pharmacists Association and the National Professional Society of Pharmacists.
...fety Knife with BD Xstar Blade includes a speciall...tects the blade in prodedure and handling. The Xs...ess for manufacturing surgical blades. This propr...nsistency. The arch style, single-bevel geometry ...
Electric high speed system.
The Durafuge 100 spins swing-out rotors at 4000 rpm and fixed-angle rotors at up to 6300 rpm.
Medicine Products: